Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Emtricitabine

Criteria

Inclusion Criteria:

1. Adult (age>18 years);

2. positive rapid HIV test;

3. ability to provide informed consent;

4. HIV RNA > 200 copies/ml;

5. creatinine clearance > 30 mg/dl as measured by serum creatinine;

6. no allergy to bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) as indicated by patient history and self-reported allergies.

Exclusion Criteria:

1) Any other comorbidities at the discretion of the investigator